NEW DRUGS ON THE PHARMACEUTICAL MARKET CONTAINING FLUORINE AND RESIDUES OF TAILOR-MADE AMINO ACIDS(Review)

• Datum: 2024
• Автори та афіліації: Jianlin Han — Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing 210037, China; Alicja Wzorek — Institute of Chemistry, Jan Kochanowski University in Kielce, Uniwersytecka 7, 25-406 Kielce, Poland; Gagan Dhawan — School of Allied Medical Sciences, Delhi Skill and Entrepreneurship University, Dwarka, 110077 New Delhi, India;; Wei Zhang — Department of Chemistry, University of Massachusetts Boston, 02125 Boston MA, Unites States;; Alexander Sorochinsky — Department of Fine Organic Synthesis, V.P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry, The National Academy of Sciences of Ukraine, 1 Murmanska str., Kyiv 02094, Ukraine; Daniel Baecker — Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Straße 2+4, 14195Berlin, Germany; Taizo Ono — National Institute of Advanced Industrial Science and Technology, 463-8560, Nagoya, Japan; Karel Klika — Molecular Structure Analysis, German Cancer Research Center (DKFZ), ImNeuenheimer Feld 280, 69120 Heidelberg, Germany; Vadim Soloshonok — University of Basque Country
• Ключові слова: keywords
• Hauptverfasser: Han, Jianlin, Wzorek, Alicja, Dhawan, Gagan, Zhang, Wei, Sorochinsky, Alexander, Baecker, Daniel, Ono, Taizo, Klika, Karel, Soloshonok, Vadim
• Format: Artikel
• Sprache: Englisch
• Veröffentlicht: V.I.Vernadsky Institute of General and Inorganic Chemistry 2024
• Online Zugang: https://ucj.org.ua/index.php/journal/article/view/689
• Назва журналу: Ukrainian Chemistry Journal

This article profiles five newly drugs containing fluorine along with fragments of amino acids or their derivatives approved by the FDA in 2024. These pharmaceuticals include Voy­deya® (danicopan), Ojemda® (tovorafenib), Itovebi® (inavolisib), Scemblix® (asciminib), and Revuforj® (revumenib). For ea...